GVAX is a whole‐cell vaccine in which pancreatic cancer cells are engineered to express the proinflammatory cytokine granulocyte monocyte‐colony stimulating factor (GM‐CSF) to further stimulate APC antigen uptake and T‐cell priming.25 A phase I study evaluated the safety and efficacy of GVAX as an adjuvant therapy given in series with chemoradiation therapy in patients with resected pancreatic cancer. Here, CSF2 is linked to familial pancreatic carcinoma.